158 related articles for article (PubMed ID: 1671830)
21. Changes in subcellular doxorubicin distribution and cellular accumulation alone can largely account for doxorubicin resistance in SW-1573 lung cancer and MCF-7 breast cancer multidrug resistant tumour cells.
Schuurhuis GJ; van Heijningen TH; Cervantes A; Pinedo HM; de Lange JH; Keizer HG; Broxterman HJ; Baak JP; Lankelma J
Br J Cancer; 1993 Nov; 68(5):898-908. PubMed ID: 8105865
[TBL] [Abstract][Full Text] [Related]
22. New potent verapamil derivatives that reverse multidrug resistance in human renal carcinoma cells and in transgenic mice expressing the human MDR1 gene.
Mickisch GH; Merlino GT; Aiken PM; Gottesman MM; Pastan I
J Urol; 1991 Aug; 146(2):447-53. PubMed ID: 1677434
[TBL] [Abstract][Full Text] [Related]
23. Evidence for reversal of multidrug resistance by quinine in LR73 cells without alteration of nuclear pirarubicin uptake and down-regulation of mdr1 gene expression.
Belhoussine R; Morjani H; Lahlil R; Manfait M
Int J Cancer; 1997 Nov; 73(4):600-6. PubMed ID: 9389578
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of the optical isomers of KR30031 on cardiotoxicity and on multidrug resistance reversal activity.
Lee BH; Lee CO; Kwon MJ; Yi KY; Yoo SE; Choi SU
Anticancer Drugs; 2003 Feb; 14(2):175-81. PubMed ID: 12569305
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of multiple drug resistance in human bladder cancer cell lines.
Shinohara N; Liebert M; Wedemeyer G; Chang JH; Grossman HB
J Urol; 1993 Aug; 150(2 Pt 1):505-9. PubMed ID: 8100862
[TBL] [Abstract][Full Text] [Related]
26. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
27. Chemosensitisation by verapamil and cyclosporin A in mouse tumour cells expressing different levels of P-glycoprotein and CP22 (sorcin).
Twentyman PR; Reeve JG; Koch G; Wright KA
Br J Cancer; 1990 Jul; 62(1):89-95. PubMed ID: 1975203
[TBL] [Abstract][Full Text] [Related]
28. SDZ 280-446, a novel semi-synthetic cyclopeptolide: in vitro and in vivo circumvention of the P-glycoprotein-mediated tumour cell multidrug resistance.
Loor F; Boesch D; Gavériaux C; Jachez B; Pourtier-Manzanedo A; Emmer G
Br J Cancer; 1992 Jan; 65(1):11-8. PubMed ID: 1346365
[TBL] [Abstract][Full Text] [Related]
29. Effect of buthionine sulfoximine and ethacrynic acid on cytotoxic activity of mitomycin C analogues BMY 25282 and BMY 25067.
Xu BH; Singh SV
Cancer Res; 1992 Dec; 52(23):6666-70. PubMed ID: 1423311
[TBL] [Abstract][Full Text] [Related]
30. Differential effects of P-glycoprotein inhibitors on NIH3T3 cells transfected with wild-type (G185) or mutant (V185) multidrug transporters.
Cardarelli CO; Aksentijevich I; Pastan I; Gottesman MM
Cancer Res; 1995 Mar; 55(5):1086-91. PubMed ID: 7866993
[TBL] [Abstract][Full Text] [Related]
31. Biochemical characterization of a mitomycin C resistant colon cancer cell line variant.
Perry RR; Kang Y; Greaves B
Biochem Pharmacol; 1993 Dec; 46(11):1999-2005. PubMed ID: 7903534
[TBL] [Abstract][Full Text] [Related]
32. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1).
Hayes MC; Birch BR; Cooper AJ; Primrose JN
BJU Int; 2001 Feb; 87(3):245-50. PubMed ID: 11167651
[TBL] [Abstract][Full Text] [Related]
33. Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.
Yang CP; DePinho SG; Greenberger LM; Arceci RJ; Horwitz SB
J Biol Chem; 1989 Jan; 264(2):782-8. PubMed ID: 2562956
[TBL] [Abstract][Full Text] [Related]
34. Combined use of tamoxifen, cyclosporin A, and verapamil for modulating multidrug resistance in human hepatocellular carcinoma cell lines.
Kim JH; Chung JB; Park IS; Kim BS; Yoo NC; Choi JH; Roh JK; Kim HS; Kwon OH; Lee KS
Yonsei Med J; 1993 Mar; 34(1):35-44. PubMed ID: 8397460
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
36. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
Huet S; Chapey C; Robert J
Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
[TBL] [Abstract][Full Text] [Related]
37. Activity of various amphiphilic agents in reversing multidrug resistance of L 1210 cells.
Pommerenke EW; Osswald H; Hahn EW; Volm M
Cancer Lett; 1990 Nov; 55(1):17-23. PubMed ID: 2245406
[TBL] [Abstract][Full Text] [Related]
38. Identification of a multidrug resistance modulator with clinical potential by analysis of synergistic activity in vitro, toxicity in vivo and growth delay in a solid human tumour xenograft.
Plumb JA; Wishart GC; Setanoians A; Morrison JG; Hamilton T; Bicknell SR; Kaye SB
Biochem Pharmacol; 1994 Jan; 47(2):257-66. PubMed ID: 8304970
[TBL] [Abstract][Full Text] [Related]
39. P-glycoprotein and alterations in the glutathione/glutathione-peroxidase cycle underlie doxorubicin resistance in HL-60-R, a subclone of the HL-60 human leukemia cell line.
Raghu G; Pierre-Jerome M; Dordal MS; Simonian P; Bauer KD; Winter JN
Int J Cancer; 1993 Mar; 53(5):804-11. PubMed ID: 8095491
[TBL] [Abstract][Full Text] [Related]
40. Reversal of multidrug resistance by an immunosuppressive agent FK-506.
Naito M; Oh-hara T; Yamazaki A; Danki T; Tsuruo T
Cancer Chemother Pharmacol; 1992; 29(3):195-200. PubMed ID: 1370765
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
